Pro-Dex, Inc. (PDEX) vs Cartesian Therapeutics, Inc. (RNAC)
A side-by-side comparison of Pro-Dex, Inc. and Cartesian Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
PDEX
Pro-Dex, Inc.
$65.37HealthcareDelayed quote: Oct 6, 2026, 1:54 PM EDT
RNAC
Cartesian Therapeutics, Inc.
$6.94HealthcareDelayed quote: Oct 6, 2026, 1:54 PM EDT
Total return — PDEX vs RNAC
growth of $100 · dividends reinvested · last 10yPDEX +1400.2% (+31.1%/yr)RNAC -98.4% (-33.9%/yr)PDEX compounded faster over this window
Log scale — wide-divergence pair
PDEX RNAC
PDEX vs RNAC: by the numbers
- •PDEX is the larger company ($209M vs $204M market cap).
- •PDEX is profitable (17.62% net margin) while RNAC runs a net loss (-10422.48%).
- •PDEX grew revenue faster over the past five years (15.32% vs -50.01% CAGR).
Metrics side by side
Valuation
| Metric | PDEX | RNAC |
|---|---|---|
| P/E ratio | 15.87 | N/A |
| Forward P/E | 21.16 | N/A |
| PEG ratio | 0.54 | N/A |
| P/S ratio | 2.69 | 138.06 |
| P/B ratio | 4.38 | N/A |
| EV / EBITDA | 15.20 | N/A |
| FCF yield | 3.30% | N/A |
Profitability
| Metric | PDEX | RNAC |
|---|---|---|
| Gross margin | 31.38% | 100.00% |
| Operating margin | 16.75% | -3099.93% |
| Net margin | 17.62% | -10422.48% |
| ROE | 28.68% | N/A |
| ROIC | 14.99% | -33.10% |
Growth (annualized)
| Metric | PDEX | RNAC |
|---|---|---|
| Revenue CAGR (5Y) | 15.32% | -50.01% |
| EPS CAGR (5Y) | 29.38% | N/A |
| Total return CAGR (5Y) | 20.45% | -44.03% |
Frequently asked
- Which has grown faster, PDEX or RNAC?
- Over the past five years, PDEX grew revenue faster — PDEX at a 15.32% CAGR versus RNAC at -50.01%.
- Is PDEX or RNAC more profitable?
- PDEX runs the higher net margin — PDEX at 17.62% versus RNAC at -10422.48%.
- How have PDEX and RNAC total returns compared?
- Over the past 10 years, PDEX delivered 31.26% and RNAC delivered -33.65% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Pro-Dex P/E ratioPro-Dex ROECartesian Therapeutics ROEPro-Dex operating marginCartesian Therapeutics operating marginPro-Dex revenue growthCartesian Therapeutics revenue growthPro-Dex free cash flowCartesian Therapeutics free cash flow
Pro-Dex & Cartesian Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.